Repository logo
 
Publication

Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma

2020Journal article Open access
Simple item page
dc.contributor.authorTeixeira, Sónia
dc.contributor.authorSantos, Miguel M.
dc.contributor.authorFernandes, Maria H.
dc.contributor.authorCosta-Rodrigues, Joao
dc.contributor.authorBranco, Luís C.
dc.date.accessioned2022-01-12T11:40:49Z
dc.date.available2022-01-12T11:40:49Z
dc.date.issued2020
dc.description.abstractHerein the quantitative synthesis of eight new mono- and dianionic Organic Salts and Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs were characterized by spectroscopic techniques and their solubility in water and biological fluids was determined. An evaluation of the toxicity towards human healthy cells and also human breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN. The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and containing an anti-resorbing molecule such as ALN may represent a promising strategy for the development of new pharmacological tools to be used in those pathological conditions.pt_PT
dc.description.sponsorshipThis work was supported by the Associate Laboratory for Green Chemistry LAQV which is financed by national funds from FCT/MCTES (UIDB/50006/2020). The authors also thank Fundação para a Ciência e Tecnologia for the projects PTDC/QUI-QOR/32406/2017, PEst-C/LA0006/2013 and RECI/BBBBQB/0230/2012), as well as one contract under Investigador FCT (L. C. Branco). The authors also acknowledge the Solchemar company.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationTeixeira, S., Santos, M. M., Fernandes, M. H., Costa-Rodrigues, J., & Branco, L. C. (2020). Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma. Pharmaceutics, 12(3), Artigo 3. https://doi.org/10.3390/pharmaceutics12030293
dc.identifier.doi10.3390/pharmaceutics12030293pt_PT
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10400.22/19425
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationPEst-C/LA0006/2013pt_PT
dc.relationAssociated Laboratory for Green Chemistry - Clean Technologies and Processes
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/12/3/293/htmpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectAlendronic acidpt_PT
dc.subjectActive Pharmaceutical Ingredientpt_PT
dc.subjectAPI-OSILspt_PT
dc.subjectAnticancer drugspt_PT
dc.subjectIonic liquidspt_PT
dc.titleAlendronic Acid as Ionic Liquid: New Perspective on Osteosarcomapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleAssociated Laboratory for Green Chemistry - Clean Technologies and Processes
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50006%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FQUI-QOR%2F32406%2F2017/PT
oaire.citation.issue3pt_PT
oaire.citation.startPage293pt_PT
oaire.citation.titlePharmaceuticspt_PT
oaire.citation.volume12pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream3599-PPCDT
person.familyNameCosta-Rodrigues
person.givenNameJoao
person.identifier.ciencia-id7412-B006-2120
person.identifier.orcid0000-0003-1375-8067
person.identifier.scopus-author-id8558383400
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationce85cc8f-09f3-4c26-aeaf-6128971acf68
relation.isAuthorOfPublication.latestForDiscoveryce85cc8f-09f3-4c26-aeaf-6128971acf68
relation.isProjectOfPublicationfc4a587f-c16e-4777-9549-2da7a1cf7d0e
relation.isProjectOfPublication918dd65b-fbb8-4fa9-b81d-ef1de95ad1be
relation.isProjectOfPublication.latestForDiscovery918dd65b-fbb8-4fa9-b81d-ef1de95ad1be

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
pharmaceutics-12-00293.pdf
Size:
2.13 MB
Format:
Adobe Portable Document Format
Download

Collections

ESS - CF - Artigos